Compare Msci Inc (MSCI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Zoetis Inc — how do they compare? Msci Inc trades at $565.48 (market cap $40.38B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Msci Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Zoetis Inc for 70 Days on average.
| MSCI | ZTS | |
|---|---|---|
Market Cap | $40.38B | $30.20B |
Volume | 414,140 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $643.83 | $147.53 |
52-Week Low | $511.84 | $69.09 |
Typical Hold Time | 82 Days | 70 Days |
Enterprise Value | $46.54B | $37.76B |
Dividend Yield | 1.48% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $565.12, up 1.75% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $3.13B, net income of $1.20B, and high margins. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 slightly missed. The company maintains strong cash flow and completed the acquisition of First Street in August 2026, enhancing its climate risk analytics offerings.
Outlook remains positive with a consensus price target of $701.71, implying significant upside. Key opportunities include recurring revenue growth and expansion in private markets. Risks include high valuation multiples, debt levels, and market sensitivity to financial services demand. Investors should weigh strong profitability against premium pricing and macroeconomic headwinds.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
